OncoMatch/Clinical Trials/NCT06998940
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Is NCT06998940 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for locally advanced pancreatic adenocarcinoma.
Treatment: Fluorouracil · Gemcitabine · Irinotecan · Irinotecan Sucrosofate · Leucovorin · Nab-paclitaxel · Panitumumab — This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil \[5-FU\] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus standard chemotherapy alone in treating patients with KRAS wild type (WT) pancreatic ductal adenocarcinoma that cannot be removed by sugery (unresectable) or that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Panitumumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Chemotherapy drugs, such as nanoliposomal irinotecan, leucovorin, 5-FU, irinotecan, nab-paclitaxel and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding panitumumab to standard chemotherapy may be effective in treating patients with unresectable, locally advanced, or metastatic KRAS WT pancreatic ductal adenocarcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Biomarker criteria
Required: KRAS wild-type
KRAS wild type (i.e. absence of any KRAS mutation)
Required: BRAF V600E wild-type
BRAF V600E wild type (i.e. absence of a BRAF V600E mutation)
Required: PTEN wild-type
Participants must not have known mutations in PTEN
Required: NRAS wild-type
Participants must not have known mutations in NRAS
Required: EGFR extracellular domain exons 1-16 wild-type
Participants must not have known mutations in EGFR extracellular domain exons 1-16
Required: HER2 (ERBB2) wild-type (no amplification)
Participants must not have known amplifications of HER2
Required: MET wild-type (no amplification)
Participants must not have known amplifications of MET
Required: RET wild-type (no fusion)
Participants must not have known gene fusions of RET
Required: NTRK1 wild-type (no fusion)
Participants must not have known gene fusions of NTRK1
Required: ALK wild-type (no fusion)
Participants must not have known gene fusions of ALK
Disease stage
Required: Stage III, IV, STAGE III AJCC V8, STAGE IV AJCC V8 (AJCC v8)
documented unresectable and/or metastatic disease on CT or magnetic resonance imaging (MRI) imaging completed prior to randomization
Performance status
ZUBROD 0–2
Prior therapy
Must have received: systemic cytotoxic chemotherapy — locally advanced or metastatic
Participants must have received only one line of prior systemic cytotoxic chemotherapy for locally advanced or metastatic PDA, and have radiographically progressed, refractory, or intolerant to this therapy.
Cannot have received: anti-EGFR antibody (cetuximab, panitumumab)
Participants must not have prior treatment with an anti-EGFR antibody (e.g., cetuximab or panitumumab)
Cannot have received: EGFR tyrosine kinase inhibitor (erlotinib)
Participants must not have prior treatment with an EGFR tyrosine kinase inhibitor (e.g., erlotinib)
Cannot have received: pancreatic anticancer therapy
Participants must not have received any pancreatic anticancer therapy (e.g., standard of care or investigational chemotherapy, molecularly targeted therapy, or radiation) within 14 days prior to randomization
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.0 x 10^3/uL; Hemoglobin ≥ 8 g/dL; Platelets ≥ 75 x 10^3/uL
Kidney function
creatinine ≤ the IULN OR measured OR calculated creatinine clearance ≥ 30 mL/min using Cockcroft-Gault Formula
Liver function
Total bilirubin ≤ 1.5 x institutional upper limit of normal (IULN); AST ≤ 10 x upper limits of normal (ULN)
Absolute neutrophil count ≥ 1.0 x 10^3/uL; Hemoglobin ≥ 8 g/dL; Platelets ≥ 75 x 10^3/uL; Total bilirubin ≤ 1.5 x institutional upper limit of normal (IULN); AST ≤ 10 x upper limits of normal (ULN); creatinine ≤ the IULN OR measured OR calculated creatinine clearance ≥ 30 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Anchorage Associates in Radiation Medicine · Anchorage, Alaska
- Alaska Breast Care and Surgery LLC · Anchorage, Alaska
- Alaska Oncology and Hematology LLC · Anchorage, Alaska
- Alaska Women's Cancer Care · Anchorage, Alaska
- Katmai Oncology Group · Anchorage, Alaska
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify